Grant: Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
University of Toronto
$105,000.00
Elucidating the Tim-3 Signaling Pathway to Identify Therapeutic Targets to Restore Immune Functioning in Progressive HIV Patients
EF 2011-12
Résumé
While the use of Highly Active Anti-Retroviral Therapies (HAART) are effective at controlling viral replication in HIV-1 infected individuals, a treatment to completely eradicate HIV-1 infected cells remains undeveloped. Natural immune processes in the body can clear HIV-infected cells, through the CD8 cytotoxic T lymphocyte (CTL) response, but is defeated by a process called exhaustion where the CTL response is diminished. This exhaustion is characterized by a biomarker called T-cell immunoglobulin and mucin domain-containing protein 3 (Tim-3), which resides on the surface of CD8 T-cells. Interaction of this molecule with its binding partner, Galectin-9 (Gal-9), results in a signaling pathway which ultimately disables the CD8 T-cell and leads to exhaustion. Our studies have shown that disrupting the Tim-3 and Gal-9 interaction helps rescue this CTL response. Thus, the goal of this project is to determine this signaling pathway, establish how these CD8 T-cells cease to be effective and disrupt this pathway to rescue immune function. Biochemical and molecular biology techniques will be used to isolate Tim-3 and study the interactions with its binding partners in the cell. Once characterized, these Tim-3 binding partners will be knocked-down to prevent their expression and disrupt the Tim-3 signaling pathway, which is hypothesized to rescue the CTL response, in a manner similar to the disruption of the Tim3-Gal-9 interaction. This would allow the immune system to battle the HIV-1 infection naturally. Thus, characterizing this pathway may lead to therapeutic targets for restoring CTL responses in HIV patients and the design of new interventions, which, in combination with HAART, could potentially cure those infected with HIV-1.
Programme
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
257411
Name
Clayton Kiera L
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Elucidating the Tim-3 Signaling Pathway to Identify Therapeutic Targets to Restore Immune Functioning in Progressive HIV Patients
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Keyworddelim
Cd8 T-Cell Exhaustion; Galectin-9; Hiv; Immune Cell Signalling; Immunology; Therapeutic Intervention; Tim-3
Abstract
While the use of Highly Active Anti-Retroviral Therapies (HAART) are effective at controlling viral replication in HIV-1 infected individuals, a treatment to completely eradicate HIV-1 infected cells remains undeveloped. Natural immune processes in the body can clear HIV-infected cells, through the CD8 cytotoxic T lymphocyte (CTL) response, but is defeated by a process called exhaustion where the CTL response is diminished. This exhaustion is characterized by a biomarker called T-cell immunoglobulin and mucin domain-containing protein 3 (Tim-3), which resides on the surface of CD8 T-cells. Interaction of this molecule with its binding partner, Galectin-9 (Gal-9), results in a signaling pathway which ultimately disables the CD8 T-cell and leads to exhaustion. Our studies have shown that disrupting the Tim-3 and Gal-9 interaction helps rescue this CTL response. Thus, the goal of this project is to determine this signaling pathway, establish how these CD8 T-cells cease to be effective and disrupt this pathway to rescue immune function. Biochemical and molecular biology techniques will be used to isolate Tim-3 and study the interactions with its binding partners in the cell. Once characterized, these Tim-3 binding partners will be knocked-down to prevent their expression and disrupt the Tim-3 signaling pathway, which is hypothesized to rescue the CTL response, in a manner similar to the disruption of the Tim3-Gal-9 interaction. This would allow the immune system to battle the HIV-1 infection naturally. Thus, characterizing this pathway may lead to therapeutic targets for restoring CTL responses in HIV patients and the design of new interventions, which, in combination with HAART, could potentially cure those infected with HIV-1.
Competitiondate
201110
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Clayton, Kiera L
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~